№14Brief2026-06-15

XH001 Trials Expand to Gastric and Pancreatic Cancers

Neoantigen vaccine development is accelerating across multiple solid tumor indications, with a notable concentration of Phase I/II trials combining personalized vaccines with PD-1/PD-L1 inhibitors or chemotherapy.

Key activity includes recruiting studies for XH001 in gastric and pancreatic cancers, while established programs like NeoVax continue to explore combination regimens in melanoma and glioblastoma.trial trial trial trial

1new story14 in context

CommercialtodayNew

The Bull Case For Moderna (MRNA) Could Change Following New Data On Its Personalized Cancer Vaccine - simplywall.st

The Bull Case For Moderna (MRNA) Could Change Following New Data On Its Personalized Cancer Vaccine simplywall.st

news · today · simplywall.st

Catching up14

Relevant work from earlier we're still surfacing — not today's news.

Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastomaclinicaltrials · 6 weeks agoNew

Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphomaclinicaltrials · Mar 2026New

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanomaclinicaltrials · Mar 2026New

Clinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancerclinicaltrials · Feb 2026New

XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancerclinicaltrials · Feb 2026New

Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal Cancerclinicaltrials · Feb 2026New

NeoVax Plus Ipilimumab in Renal Cell Carcinomaclinicaltrials · Feb 2026New

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumorsclinicaltrials · Jan 2026New

Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgeryclinicaltrials · Jan 2026New

Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanomaclinicaltrials · Jan 2026New

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumorsclinicaltrials · Nov 2025New

Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancerclinicaltrials · Oct 2025New

Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRCclinicaltrials · Sep 2025New

A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomasclinicaltrials · Sep 2025New